Fig. 5.

HIPK2 inhibition mediates cardiac protection through downregulating P-P53. (a) P-P53 (S15)/P53 were reduced in the heart of swimming mice (n=3 per group); (b) Cardiac P-P53 (S15)/P53 were increased in post-MI remodeling for 9 weeks and 8-week-running training decreased cardiac P-P53 (S15)/P53 during post-MI remodeling (n=3 per group); (c) Cardiac P-P53 (S15)/P53 were increased in post-MI remodeling for 3 weeks and HIPK2^–/– mice decreased cardiac P-P53 (S15)/P53 during post-MI remodeling (n=3 per group); (d) Cardiac P-P53 (S15)/P53 were increased in post-MI remodeling for 3 weeks and PKI1H decreased cardiac P-P53 (S15)/P53 during post-MI remodeling (n=3 per group); (e) Immunoprecipitation (IP) and immunoblotting were performed using the antibodies indicated and showed that HIPK2 interacted with P53; (f and g) P53 activators (CTX1 and DPBQ) increased TUNEL staining in NRCMs under OGD/R infected with lenti-sh-HIPK2 (n=6 per group in f and n=4 per group in g); (h and i) CTX1 and DPBQ increased Bax/Bcl₂, cleaved Caspase3/Caspase3 in NRCMs under OGD/R infected with lenti-sh-HIPK2 (n=3 per group). Scale bar: 100μm. Data are represented as mean ± SD. Significant differences were assessed by two-tailed student t-test in a, or two-way ANOVA followed by Bonferroni's multiple comparisons test in b-i. *: p<0.05, **: p<0.01, ***: p<0.001 versus respective control.